Acorda Therapeutics. has been granted a patent for sustained release 4-aminopyridine tablets designed for once daily oral administration. The formulation includes a compressed core with specific percentages of 4-aminopyridine, polyethylene oxide, and a polyvinyl mixture, coated with ethylcellulose. GlobalData’s report on Acorda Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Acorda Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Acorda Therapeutics's grant share as of June 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Sustained release 4-aminopyridine tablets for neurological disorders
The granted patent US12029820B2 describes a sustained release tablet formulation primarily containing 4-aminopyridine, a compound used in various therapeutic applications. The tablet's core is composed of 4-aminopyridine in concentrations ranging from 1% to 10% w/w, along with polyethylene oxide (10% to 20% w/w) and a mixture of polyvinyl acetate and polyvinyl pyrrolidone (20% to 30% w/w). The core is coated with ethylcellulose, which constitutes 5% to 10% w/w of the total core weight. The formulation is designed to provide a controlled release of 4-aminopyridine, ensuring therapeutic effectiveness over a 24-hour period with a zero-order or near-zero-order release profile.
Additional claims detail the specific composition of the core, including the potential inclusion of excipients, fillers, and lubricants. The patent outlines various formulations with precise ratios of the components, such as the mixture of polyvinyl acetate and polyvinyl pyrrolidone, and the use of dibasic calcium phosphate dihydrate and magnesium stearate. The method of manufacturing the tablet involves curing the coated core at elevated temperatures to enhance the release characteristics. The patent also specifies the in vitro dissolution profile, indicating that less than 30% of the active ingredient is released within the first two hours, with at least 80% released over 24 hours, thereby confirming the sustained release nature of the tablet.
To know more about GlobalData’s detailed insights on Acorda Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
